Baseline characteristics of patients with included anti-topoisomerase I antibodies positive SSc categorised in groups based on time between RP and non-RP
| Total: n=161 | ≤3 months n=55 | 4 to ≤24 months n=54 | ≥25 months n=52 | P value | |
| Age, mean (SD) | 52 (15) | 53 (15) | 52 (13) | 51 (16) | 0.848 |
| Female, n (%) | 106 (65) | 29 (53) | 40 (74) | 36 (69) | 0.035 |
| Years follow-up, median (min; max) | 3 (0; 11) | 3 (0; 11) | 5 (0; 11) | 3 (0; 10) | 0.105 |
| Modified Rodnan Skin Score, median (IQR) | 6 (2–12) | 9 (5–17) | 5 (2–14) | 4 (2–7) | 0.002 |
| Limited cutaneous SSc, n (%) | 79 (48) | 22 (40) | 19 (35) | 36 (69) | 0.004 |
| Diffuse cutaneous SSc, n (%) | 70 (43) | 29 (53) | 28 (52) | 12 (23) | |
| Digital ulcers, n (%) | 21 (13) | 8 (15) | 7 (13) | 6 (12) | 0.879 |
| ILD on HRCT, n (%) | 103 (63) | 35 (64) | 19 (63) | 33 (64) | 0.690 |
| ILD combined, n (%) | 41 (25) | 17 (31) | 15 (28) | 8 (15) | 0.158 |
| First non-RP symptoms, n (%) | 0.090 | ||||
| 78 (48) | 23 (49) | 35 (66) | 20 (44) | |
| 28 (17) | 12 (28) | 5 (9) | 9 (20) | |
| 17 (10) | 5 (11) | 4 (8) | 8 (17) | |
| 4 (3) | – | 3 (6) | 1 (2) | |
| 17 (10) | 6 (13) | 3 (6) | 7 (15) | |
| – | – | – | – | |
| 2 (1) | – | 1 (2) | 1 (2) | |
| 2 (1) | – | 2 (4) | – |
HRCT, high-resolution CT; ILD, interstitial lung disease; N, number; RP, Raynaud's Phenomenon; SSc, systemic sclerosis.